Navigation Links
Evidence now suggests eating soy foods in puberty protects against breast cancer
Date:4/9/2008

Washington, D.C. Evidence is growing from animal and human studies that genistein, a potent chemical found in soy, protects against development of breast cancer - but only if consumed during puberty, says a Georgetown University Medical Center researcher in the British Journal of Cancer published online today. The challenge now, she says, is for scientists to understand precisely why soy appears to provide a shield against the most common cancer in women.

Timing seems to be vitally important in use of this bioactive food, and if we can figure out why that is so, then we may be able to help prevent breast cancer in the widest sense possible, says the researcher, Leena Hilakivi-Clarke, Ph.D., a professor of oncology at the Lombardi Comprehensive Cancer Center at Georgetown.

Although there are a number of tantalizing theories to explain the connection, at the present time no convincing explanation can be offered as to why the breast cancer-risk reducing effect of genistein might be strongest during childhood and early adolescence, she says.

Hilakivi-Clarke is a senior author of a review article published in the journal that sums up the state of knowledge concerning the role of early life genistein exposures in modifying breast cancer risk. She has long studied the link between soy use and breast cancer, as have her three co-authors, all Finnish researchers.

There have only been three human studies that tracked soy use during puberty and later breast cancer development, and two of them focused on Asian females, who eat soy in their traditional diet. But these studies suggest soy offers a very strong protective effect a 50 percent or more reduction in the risk of breast cancer - when soy is eaten during childhood and adolescence.

The strongest evidence for genisteins protective effect comes from studies in mice and rats, Hilakivi-Clarke says. For example, numerous studies in rats show that the data regarding prepubertal exposure to genistein are very consistent in showing a reduction in mammary cancer risk, she says. Exposure to soy in fetal development or in adult life does not have the same protective effect.

Further examination of experimental versus control rats demonstrated that use of genistein in puberty cut the number of so-called terminal end buds in the breast. These are the structures that lead to growth of the mammary epithelium, which are the cells lining milk ducts, etc., and it is in these epithelial cells that breast cancer originates. But Hilakivi-Clarke says it is not clear if a mere reduction in the number of these structures could reduce cancer risk, or why.

Other studies suggest that genistein controls expression of genes in terminal end buds that regulate cell growth, repair and death. For example, the chemical could be controlling the ability of stem cells, found on these buds, to reproduce themselves or to differentiate into more specialized cells. There is evidence that suggests that the more stem cells there are on these structures, the greater the risk of breast cancer development, she says. This evidence supports the theory that breast cancer arises from stem cells that have lost growth control.

Other associated research has found that the genes that genistein appears to activate in developing mammary glands are well known --- BRCA1, p53, and PTEN tumor suppressors, Hilakivi-Clarke says. These genes repair genetic damage and control cell survival and death, and they may also help control stem cell reproduction, she says, and genistein apparently up-regulates these genes, boosting production of their beneficial proteins.

What is perhaps most intriguing, she says, is that the same process that protects the breast from excess growth during pregnancy seems to be at work during puberty. In pregnancy, BRCA1 is also up-regulated, perhaps in order to control the fate of stem cells, allowing them to make more cells for milk production, for example, but not more of themselves.

So Hilakivi-Clarke favors the notion that genistein is acting as a breast cancer protective just as an early first pregnancy in women is known to protect against later development of the cancer:

If malignancies occur in breast stem cells, then it is better that many of these cells are differentiated earlier rather than later. Pregnancy hormones do that, so the shorter time there is between puberty and pregnancy, the greater that protection may be, she says. Genistein may also help control the fate of stem cells in the same way.

We think this is the mechanism by which genistein works, but we really dont know and we need to find out, Hilakivi-Clarke says. The findings will matter.


'/>"/>

Contact: Karen Mallet
km463@gmail.com
414-312-7085
Georgetown University Medical Center
Source:Eurekalert

Related biology news :

1. A private bandwidth for communication in bats: Evidence from insular horseshoe bats
2. Comet probes reveal evidence of origin of life, scientists claim
3. Evidence of a relationship between swimming babies and infections
4. Researchers find evidence linking stress caused by the Sept. 11 disaster with low birth weights
5. Fossil record supports evidence of impending mass extinction
6. New evidence for female control in reproduction
7. RAND study finds evidence disease management programs
8. CWRU School of Medicine has evidence vaccine against malaria will reduce disease
9. There is powerful evidence of evolution in human DNA
10. Scientific evidence supporting evolution continues to grow
11. No convincing evidence for decline in tropical forests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:5/24/2016)... -- Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the ... latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Display- Ampronix News ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology: